HER2-positive Breast Cancer Clinical Trials in Milan
9 recruitingMilan, Italy
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Not Applicable
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
HER2-positive Breast CancerEarly Stage Breast Cancer
Fundacio Clinic Barcelona304 enrolled29 locationsNCT06446882
Recruiting
Phase 3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals550 enrolled166 locationsNCT06435429
Recruiting
Not Applicable
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
Triple-Negative Breast CancerInvasive Breast CancerHER2-positive Breast Cancer
European Institute of Oncology145 enrolled1 locationNCT06328465
Recruiting
Phase 2
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
HER2-positive Breast Cancer
MedSIR165 enrolled36 locationsNCT06172127
Recruiting
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Breast CancerBreast Cancer MetastaticBreast Carcinoma+13 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano500 enrolled1 locationNCT07030569
Recruiting
Phase 2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
HER2-positive Breast Cancer
GBG Forschungs GmbH170 enrolled29 locationsNCT05306041
Recruiting
Not Applicable
Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery
Breast CancerTriple-Negative Breast CancerHER2-positive Breast Cancer+1 more
European Institute of Oncology77 enrolled2 locationsNCT06281210